https://orcid.org/0000-0001-7862-6511
REFERENCES
- Friesen, P., L. Gelinas, A. Kirby, D. H. Strauss, and B. E. Bierer. 2023. IRBs and the protection-inclusion dilemma: Finding a balance. The American Journal of Bioethics 23 (6):75–88. doi:10.1080/15265161.2022.2063434.
- Gold, J. L., and C. S. Dewa. 2005. Institutional review boards and multisite studies in health services research: Is there a better way? Health Services Research 40 (1):291–307. doi:10.1111/j.1475-6773.2005.00354.x.
- Green, A. K., N. Trivedi, J. J. Hsu, N. L. Yu, P. B. Bach, and S. Chimonas. 2022. Despite the FDA’s five year plan, black patients remain inadequately represented in clinical trials for drugs. Health Affairs 41 (3):368–74. doi:10.1377/hlthaff.2021.01432.
- NASEM (National Academies of Sciences, Engineering, and Medicine). 2022. Improving representation in clinical trials and research: Building research equity for women and underrepresented groups. Washington, DC: The National Academies Press. doi:10.17226/26479.
- OHRP (Office of Human Research Protection). 2022. Determination Letter “RE: Human Research Subject Protections under IORG0000434, Federalwide Assurance FWA00000337.” July 13, https://www.hhs.gov/ohrp/compliance-and-reporting/determination-letters/2022/july-13-2022-biomedical-research-alliance-of-new-york-brany/index.html.
- Rajadhyaksha, V. 2010. Conducting feasibilities in clinical trials: An investment to ensure a good study. Perspectives in Clinical Research 1 (3):106–9.
- Ratti, P., and S. J. Squires. 2023. A guide to maintaining clinical trial integrity in Catholic health care. Health Progress 104 (1):19–23.